查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014273

伴隨診斷市場：依產品類型、應用、最終用戶和通路分類－2026-2032年全球市場預測

Companion Diagnostics Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，伴隨診斷市場價值將達到 37.9 億美元，到 2026 年將成長至 41.3 億美元，到 2032 年將達到 69.6 億美元，複合年成長率為 9.04%。

主要市場統計數據
基準年 2025 37.9億美元
預計年份：2026年 41.3億美元
預測年份 2032 69.6億美元
複合年成長率 (%) 9.04%

權威說明指出伴隨診斷如何重新定義臨床路徑以及在診斷、治療和醫療保健服務領域的策略價值。

伴隨診斷正在改變實驗室科學與臨床決策的交匯點，從而實現更精準的患者分層和標靶治療選擇。該領域已從支持單藥聯合治療的細分市場發展成為現代精準醫療策略的重要組成部分，影響著法規核准流程、臨床試驗設計和商業性價值提案。隨著生物標記和伴隨檢測在治療方法研發中日益佔據主導地位，診斷工具正從輔助產品轉變為策略性資產，影響著治療流程的發展以及與保險公司的互動。

分子技術的進步、監管的調整以及整合的臨床工作流程如何重塑伴隨診斷和臨床應用。

伴隨診斷領域正經歷著一場變革性的轉變，這場變革是由技術、監管和臨床實踐等多面向因素共同推動的。定序技術和多種檢測方法的進步拓展了診斷選擇，使臨床醫生能夠從檢測單一分析物轉向全面的分子譜分析，從而揭示複雜疾病的生物學機制。這一發展趨勢，加上真實世界數據（REW）和適應性臨床試驗框架日益被接受，正在縮短從生物標記發現到臨床應用的時間，並為迭代檢驗創造了新的機會。

對關稅政策變更對診斷試劑和檢查室的供應鏈、籌資策略和業務永續營運的影響進行系統性評估。

近期政策週期中宣布或實施的貿易政策和關稅措施的變化，為伴隨診斷價值鏈引入了新的變量，影響了試劑採購、儀器採購和國際檢查室夥伴關係。對檢測設備、昂貴的定序設備和進口試劑徵收的關稅可能會改變供應商選擇的動態，並促使企業採取在地採購策略。為此，許多相關人員開始重新評估供應商關係，尋求關鍵材料的雙重來源，並探索在地化生產方案，以降低貿易相關的成本波動風險。

我們根據細分市場主導的洞察，制定產品開發和商業化策略，使檢測方法、臨床應用、使用者需求和分銷管道保持一致。

有效的細分分析能夠揭示技術優勢與臨床需求和商業性機會的交會點。從檢測方法學的角度來看，免疫組織化學提供了成熟的基於組織的生物標記測量方法，這在許多病理工作流程中仍然至關重要。另一方面，原位雜合反應透過核酸定位來補充組織分析。次世代定序拓展了診斷的廣度和深度，並進一步細分為標靶定序（專注於與可操作突變相符的特定基因組）、轉錄組定序（捕獲與機制闡明和抗藥性監測相關的基因表現表現譜）和全基因測序（為複雜病例提供全面的基因組背景）。聚合酵素鏈鎖反應(PCR) 因其速度和靈敏度而仍然非常重要，並且包括一些特殊形式，例如用於絕對定量的數位 PCR 和用於高通量相對定量的定量 PCR。

區域醫療保健基礎設施、監管方法和戰略夥伴關係如何推動美洲、歐洲、中東、非洲和亞太地區差異化的部署模式。

伴隨診斷的區域發展趨勢受其各自的醫療基礎設施、監管方式和投資生態系統的影響。在美洲，整合的醫療服務提供者、強大的臨床試驗網路和大規模的生物技術產業正在推動新型診斷技術的早期應用，並促進臨床醫生與產業界的密切合作。這種環境有利於進行迭代檢驗和臨床效用研究，從而將研究成果與臨床路徑連接起來，同時，醫保報銷的討論也越來越側重於價值證明和結果一致性。

深入了解決定診斷開發公司、檢測實驗室和綜合服務供應商成功的競爭定位、夥伴關係和能力建設。

伴隨診斷領域的競爭動態是由專業檢測方法開發公司、儀器製造商、臨床實驗室網路以及整合診斷和治療的夥伴關係共同塑造的。在分析化學、分子生物學或病理學領域擁有深厚專業知識的公司，利用其專有平台和檢驗的工作流程來建立臨床可靠性。同時，那些兼具可擴展生產能力、法規遵循經驗和協作開發模式的公司，則展現出加速伴隨診斷臨床應用和市場准入的能力。

診斷開發公司和醫療保健系統在協調創新、供應鏈韌性和協作證據產生方面面臨的實際策略挑戰。

產業領導者應優先應對幾項策略挑戰，以有效應對瞬息萬變的診斷格局。首先，他們必須將產品開發與可驗證的臨床實用性和操作可行性相結合，具體做法包括：將最終用戶效用融入診斷方法的設計中，在代表性工作流程中檢驗效能，並確保報告結果能夠整合到臨床決策流程中。這種一致性能夠減少部署阻力，並有助於與支付方展開更著重於改善治療效果而非分析新穎性的討論。

透過透明的混合方法研究框架，結合專家訪談、監管文件分析和案例研究整合，我們得出實用的診斷見解。

本研究途徑旨在透過整合定性和定量方法，整體情況伴隨診斷。主要資訊來源包括對臨床意見領袖、檢查室管理者、監管專家和相關人員的訪談，以識別營運挑戰、應用促進因素和未滿足的需求。從這些對話中獲得的見解將有助於建立一個框架，用於評估分析平台、檢測性能特徵以及在實際臨床工作流程中的整合障礙。

為了指導對伴隨診斷的策略性投資及其在臨床實踐中的應用，我們總結了技術、監管和商業性要求。

總而言之，伴隨診斷在精準醫療中扮演日益重要的角色，重塑臨床路徑、臨床實驗設計和經營模式。定序和多重檢測技術的進步，以及監管和報銷政策的持續演進，都提高了人們對伴隨診斷臨床效用和營運準備的期望。隨著供應鏈和貿易政策趨勢日益複雜，韌性和策略採購已成為商業化規劃的關鍵要素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：伴隨診斷市場：依產品類型分類

  • 免疫組織化學
  • 原位雜合反應
  • 次世代定序
    • 目標序列
    • 轉錄組序列
    • 全基因組定序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 定量PCR

第9章：伴隨診斷市場：依應用領域分類

  • 遺傳性疾病
  • 感染疾病
  • 腫瘤學
  • 藥物基因體學

第10章：伴隨診斷市場：依最終用戶分類

  • 學術研究機構
  • 診斷檢查室
  • 醫院
  • 製藥公司

第11章：伴隨診斷市場：依通路分類

  • 直接競標
  • 透過分銷商銷售
  • 線上銷售

第12章 伴隨診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：伴隨診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 伴隨診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國伴隨診斷市場

第16章：中國伴隨診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abnova Corporation
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • Almac Group
  • Amoy Diagnostics Co., Ltd.
  • ARUP Laboratories
  • Bio-Techne Corporation
  • Biogenex Laboratories, Inc
  • bioMerieux SA
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Guardant Health, Inc
  • ICON PLC
  • Illumina, Inc.
  • Invivoscribe Technologies, Inc.
  • Myriad Genetics, Inc.
  • NG biotech
  • QIAGEN NV
  • R-Biopharm AG
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-433AB1DC2871

The Companion Diagnostics Market was valued at USD 3.79 billion in 2025 and is projected to grow to USD 4.13 billion in 2026, with a CAGR of 9.04%, reaching USD 6.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.79 billion
Estimated Year [2026] USD 4.13 billion
Forecast Year [2032] USD 6.96 billion
CAGR (%) 9.04%

An authoritative introduction to how companion diagnostics are redefining clinical pathways and strategic value across diagnostics, therapeutics, and healthcare delivery

Companion diagnostics are changing the interface between laboratory science and clinical decision-making, enabling more precise patient stratification and targeted therapy selection. The field has matured from a niche enabler of single-drug pairings to an integral component of modern precision medicine strategies, influencing regulatory review pathways, clinical trial designs, and commercial value propositions. As therapeutic development increasingly prioritizes biomarkers and companion tests, diagnostic tools have transitioned from adjunctive products to strategic assets that shape treatment algorithms and payer conversations.

In parallel, technological advances and cross-disciplinary collaborations have broadened the applications of companion diagnostics. Innovations in molecular profiling, digital pathology, and data analytics have created richer diagnostic signals that inform both therapeutic selection and longitudinal disease management. This introduction outlines the drivers shaping the companion diagnostics environment, frames the interplay between clinical utility and commercial adoption, and sets expectations for how stakeholders can align operational capabilities with evolving clinical and regulatory demands.

How converging advances in molecular technology, regulatory adaptation, and integrated clinical workflows are reshaping companion diagnostics and clinical adoption

The companion diagnostics landscape is undergoing transformative shifts driven by converging forces in technology, regulation, and clinical practice. Advances in sequencing technologies and multiplexed assays have expanded the diagnostic repertoire, enabling clinicians to move beyond single-analyte tests toward comprehensive molecular profiling that captures complex disease biology. This evolution is paired with increasing acceptance of real-world evidence and adaptive clinical trial frameworks, which together compress the timeline from biomarker discovery to clinical adoption and create new opportunities for iterative validation.

Regulatory frameworks are adapting to these advances, with agencies emphasizing analytical robustness, clinical relevance, and post-market evidence generation. Payers and health systems are recalibrating reimbursement models to consider diagnostic-driven therapeutic value, prompting developers to demonstrate cost-effectiveness and patient outcome improvements. At the same time, digital integration and laboratory automation are reducing turnaround times and improving reproducibility, which enhances clinician confidence and supports broader workflow integration. These shifts collectively elevate the role of diagnostics in precision medicine while also introducing complexity in commercialization strategies, supply chain planning, and cross-stakeholder evidence generation.

As diagnostics mature, partnerships between diagnostic developers, pharmaceutical sponsors, and clinical laboratories are becoming more strategic and sophisticated. Collaborative evidence generation and co-development agreements are enabling more aligned go-to-market strategies, while data-sharing consortia are accelerating biomarker validation. These trends signal a more integrated ecosystem in which diagnostics not only inform therapeutic decisions but also play a central role in clinical development and market access planning.

Assessing the systemic consequences of evolving tariff policies on diagnostics supply chains, procurement strategies, and laboratory operational resilience

Trade policy shifts and tariff measures announced or implemented in recent policy cycles have introduced new variables into the supply chains that underpin companion diagnostics, with implications for reagent procurement, instrument sourcing, and international laboratory partnerships. Tariffs on laboratory equipment, high-value sequencing instruments, and imported reagents can alter supplier selection dynamics and motivate localized sourcing strategies. In response, many stakeholders have started reassessing vendor relationships, dual-sourcing critical inputs, and exploring regionalized manufacturing options to mitigate exposure to trade-related cost volatility.

Beyond direct procurement costs, tariffs influence capital planning for clinical laboratories and diagnostic manufacturers that rely on imported instrumentation. Procurement cycles are adapting as buyers delay or accelerate purchases to navigate tariff windows, and vendors are revising channel strategies to preserve competitiveness. Moreover, tariff-driven changes in logistics and customs processing can affect lead times, which in turn influence inventory management and service level commitments to clinical partners. In this context, firms with flexible supply arrangements and in-region manufacturing or distribution capabilities are better positioned to sustain operations without sacrificing service quality.

Stakeholders should view tariff impacts through a systems lens, considering not only incremental cost pressures but also the operational friction that arises from altered trade flows. Strategic responses include renegotiating long-term supplier contracts with tariff contingencies, investing in local assembly or reagent blending where regulatory pathways permit, and enhancing scenario planning to anticipate future trade shifts. These measures help maintain continuity of testing services and support resilient commercialization pathways despite external policy fluctuations.

Segment-driven insights that align assay modality, clinical application, user needs, and distribution channels to inform product development and commercialization strategies

Effective segmentation analysis illuminates where technical strengths intersect with clinical demand and commercial opportunity. When products are viewed through the lens of assay modality, Immunohistochemistry offers established tissue-based biomarker readouts that remain essential for many pathology workflows, while In Situ Hybridization complements tissue analysis with nucleic acid localization. Next Generation Sequencing expands diagnostic breadth and depth and is further differentiated by Targeted Sequencing, which focuses on specific gene panels aligned to actionable variants; Transcriptome Sequencing, which captures gene expression profiles relevant to mechanism elucidation and resistance monitoring; and Whole Genome Sequencing, which provides comprehensive genomic context for complex cases. Polymerase Chain Reaction retains prominence for its speed and sensitivity and includes specialized forms such as Digital PCR for absolute quantitation and Quantitative PCR for high-throughput relative quantitation.

Application-focused segmentation reveals where testing drives clinical decision-making and where development resources should be concentrated. Genetic Disorders present opportunities for early detection and family risk assessment, Infectious Diseases require rapid, sensitive platforms for pathogen identification and resistance profiling, Oncology continues to be the dominant clinical driver for companion diagnostics through precise targeting of therapies, and Pharmacogenomics supports safer and more effective medication selection across therapeutic areas. Each application imposes distinct analytical requirements and validation paradigms, influencing both technology choice and clinical implementation strategies.

End-user segmentation shapes distribution models and service delivery expectations. Academic and research institutes often prioritize flexibility and depth of analysis for discovery and translational work, while diagnostic laboratories emphasize throughput, regulatory compliance, and reproducibility. Hospitals integrate testing into clinical workflows and prioritize turnaround time and clinical reporting, whereas pharmaceutical companies focus on companion diagnostic alignment with therapeutic pipelines and clinical trial integration. Distribution channel segmentation further affects market access, with direct tender arrangements supporting institutional procurement, distributor sales facilitating broader geographic reach, and online sales enabling rapid ordering of kits and consumables for decentralized testing environments. Together, these segmentation dimensions provide a layered view of product-market fit and guide prioritization of development, commercialization, and customer support investments.

How regional healthcare infrastructure, regulatory approaches, and strategic partnerships drive differentiated adoption patterns across the Americas, Europe Middle East and Africa, and Asia-Pacific

Regional dynamics in companion diagnostics are shaped by distinct healthcare infrastructures, regulatory approaches, and investment ecosystems. In the Americas, integrated healthcare providers, robust clinical trial networks, and a large biotechnology sector foster early adoption of novel diagnostics and close clinician-industry collaboration. This environment supports iterative validation and clinical utility studies that bridge research findings with clinical pathways, while reimbursement dialogues increasingly center on value demonstration and outcome alignment.

Europe, the Middle East & Africa display heterogeneous adoption curves influenced by diverse regulatory regimes and payer landscapes. Robust academic centers and centralized public health systems in parts of Europe facilitate multicenter collaborations and standardization efforts, whereas markets across the Middle East and Africa often emphasize capacity building, laboratory infrastructure modernization, and regional harmonization. Cross-border partnerships and diagnostic hubs play a vital role in extending advanced testing capabilities to broader patient populations in these regions.

The Asia-Pacific region is notable for rapid investment in laboratory infrastructure, growing domestic diagnostic manufacturing, and large patient cohorts that enable translational research and real-world evidence generation. Government-led initiatives to expand precision medicine programs and the presence of high-volume clinical sites create opportunities for scaling diagnostic services. Across regions, stakeholders must navigate differing regulatory timelines, reimbursement frameworks, and infrastructure constraints, tailoring market entry and partnership strategies to regional realities while leveraging global evidence generation to support broader adoption.

Insights into competitive positioning, partnerships, and capability stacks that determine success for diagnostic developers, laboratories, and integrated service providers

Competitive dynamics in companion diagnostics are shaped by a mix of specialized assay developers, instrument manufacturers, clinical laboratory networks, and integrated diagnostic-therapeutic partnerships. Companies with deep expertise in analytical chemistry, molecular biology, or pathology have leveraged proprietary platforms and validated workflows to establish clinical credibility. At the same time, firms that combine scalable manufacturing, regulatory experience, and collaborative development models have shown an ability to accelerate clinical translation and market entry for companion tests.

Strategic collaborations between diagnostic developers and pharmaceutical sponsors remain a critical pathway for co-developing tests that align tightly with therapeutic modalities. These partnerships often extend into evidence generation, coding and reimbursement strategy, and post-market surveillance. In addition, laboratory service providers that deliver end-to-end testing capabilities, including centralized and distributed service models, play a vital role in bridging innovation with clinical access. Companies that invest in robust quality systems, interoperability with electronic health records, and clinician-facing reporting tools tend to achieve stronger adoption and integration into care pathways.

Emerging competitive pressure comes from firms that combine diagnostics with advanced analytics and decision-support solutions, enabling more actionable, longitudinal interpretations of biomarker data. These hybrid offerings suggest the market is shifting toward value propositions that marry analytical performance with clinical utility and workflow efficiency, rewarding organizations that can demonstrate tangible improvements in patient management and health system outcomes.

Actionable strategic imperatives for diagnostic developers and health systems to align innovation, supply chain resilience, and collaborative evidence generation

Industry leaders should prioritize a few strategic imperatives to navigate the evolving diagnostics environment effectively. First, align product development with demonstrable clinical utility and operational feasibility by embedding end-user needs into assay design, validating performance across representative workflows, and ensuring reporting outputs integrate with clinical decision-making processes. This alignment reduces adoption friction and supports payer discussions focused on outcome improvements rather than analytic novelty.

Second, strengthen supply chain resilience by diversifying suppliers, considering regional manufacturing or assembly where feasible, and incorporating tariff and logistics scenarios into procurement planning. Proactive vendor partnerships and long-term agreements with contingency clauses can reduce exposure to trade and distribution disruptions and support reliable laboratory operations.

Third, cultivate strategic collaborations with pharmaceutical sponsors, clinical networks, and health systems to co-generate evidence and accelerate clinical integration. These collaborations should be structured to share risks and align incentives around demonstrable patient benefits. Investing in data infrastructure and analytics capabilities enables more persuasive real-world evidence generation and continuous performance monitoring.

Finally, invest in commercialization models that reflect end-user realities, including hybrid distribution approaches that combine direct institutional engagement, distributor partnerships, and digital channels for consumables. Complementing product innovation with clinician education, payer engagement plans, and streamlined regulatory strategies will increase the likelihood of successful uptake and sustained clinical use.

A transparent mixed-methods research framework combining expert interviews, regulatory document analysis, and case study synthesis to derive actionable diagnostic insights

The research approach blends qualitative and quantitative techniques to produce a comprehensive understanding of the companion diagnostics landscape. Primary inputs include interviews with clinical thought leaders, laboratory directors, regulatory experts, and commercial stakeholders to capture operational challenges, adoption drivers, and unmet clinical needs. These conversations inform a framework for evaluating analytical platforms, assay performance characteristics, and integration barriers within real-world clinical workflows.

Secondary research encompasses a broad review of peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and public policy statements to ground the analysis in current scientific and regulatory context. Comparative case studies of successful diagnostic-therapeutic co-development efforts were analyzed to extract best practices and common pitfalls in evidence generation, regulatory strategy, and market access planning.

Synthesis involved triangulating primary and secondary findings to develop scenario-based implications for supply chain design, commercialization pathways, and regional entry strategies. Validation workshops with industry stakeholders were used to refine conclusions and ensure practical relevance. This mixed-methods design emphasizes transparency in assumptions, traceability of insights to source inputs, and actionable recommendations tailored to organizational decision-making needs.

Concise conclusion synthesizing technological, regulatory, and commercial imperatives to guide strategic investments and clinical integration of companion diagnostics

In summary, companion diagnostics are increasingly central to precision medicine, reshaping clinical pathways, trial designs, and commercial models. Technological advancements in sequencing and assay multiplexing, coupled with evolving regulatory and reimbursement dialogues, are elevating the expectations for clinical utility and operational readiness. Supply chain and trade policy dynamics add complexity, making resilience and strategic sourcing essential components of commercialization planning.

Segmentation across product type, application, end user, and distribution channel highlights distinct development and go-to-market requirements, while regional dynamics require tailored strategies that reflect infrastructure, regulatory, and payer differences. Competitive advantage accrues to organizations that combine analytical excellence with robust evidence generation, strategic partnerships, and clinician-aligned reporting and workflow integration. Taken together, these insights provide a coherent foundation for leaders seeking to prioritize investments and accelerate clinical integration of companion diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Diagnostics Market, by Product Type

  • 8.1. Immunohistochemistry
  • 8.2. In Situ Hybridization
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Polymerase Chain Reaction
    • 8.4.1. Digital Pcr
    • 8.4.2. Quantitative Pcr

9. Companion Diagnostics Market, by Application

  • 9.1. Genetic Disorders
  • 9.2. Infectious Diseases
  • 9.3. Oncology
  • 9.4. Pharmacogenomics

10. Companion Diagnostics Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Pharmaceutical Companies

11. Companion Diagnostics Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Distributor Sales
  • 11.3. Online Sales

12. Companion Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Companion Diagnostics Market

16. China Companion Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Abnova Corporation
  • 17.7. Agendia, Inc.
  • 17.8. Agilent Technologies, Inc.
  • 17.9. Almac Group
  • 17.10. Amoy Diagnostics Co., Ltd.
  • 17.11. ARUP Laboratories
  • 17.12. Bio-Techne Corporation
  • 17.13. Biogenex Laboratories, Inc
  • 17.14. bioMerieux SA
  • 17.15. Danaher Corporation
  • 17.16. Eli Lilly and Company
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. Guardant Health, Inc
  • 17.19. ICON PLC
  • 17.20. Illumina, Inc.
  • 17.21. Invivoscribe Technologies, Inc.
  • 17.22. Myriad Genetics, Inc.
  • 17.23. NG biotech
  • 17.24. QIAGEN N.V.
  • 17.25. R-Biopharm AG
  • 17.26. Siemens AG
  • 17.27. Sysmex Corporation
  • 17.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 136. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 157. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 158. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 165. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)